2023年加拿大肾癌论坛共识声明：肾细胞癌的辅助治疗(1)

CKCF CONSENSUS STATEMENTAdjuvant therapy for renal cell carcinoma:2023 Canadian Kidney Cancer Forumconsensus statementadjuvant immunotherapy,were discussed.ParticipantsAly-Khan A.Lalani',Anil Kapoor2,Naveen S.Basappa,Bimal Bhindi,were asked to vote if they agreed or disagreed with eachGeorg A.Bjarnason5,Dominick Bosses,Rodney H.Breau?,statement.Consensus was achieved if greater than 75%ofChristina M.Canils,Luisa M.Cardenas',Vincent Castonguay,particpants agreed with the topic statement.Claudia Chavez-Munoz,William Chu5,Shaan DudaniJeffrey Graham",DanielY.C.Heng2,Christian KollmannsbergerRESULTS:A total of 22 RCC experts voted on 14Jean-Baptiste Lattouf,Scott Morgan'5,M.Neil Reaumes,statements.Consensus was achieved on all topicPatrick O.Richards,Anand Swaminath7,Simon Tanguay,statements.The panel felt patients with clear-cell RCCLori A.Wood,9 Luke T.Lavallee20at increased risk of recurrence after surgery,as perthe Keynote-564 group definitions,should be coun-'Department of Medical Oncology,luravinski Cancer Centre McMaster.Hamiton,ON.CanadaaSt oseph's Heathcare Hamiton,MMaster University.Hamilton.ON.Canada:Department ofselled about recurrence risk by a urologist,should beOncology.Cross Cancer Institute.University of Alberta.Edmonton.AB CanadSouthem Abertainformed about the potential role of adjuvant ICl sys-Institute of Urdlogy.Cumming Schodl of Medicne,University of Calgary.Calgary.AB CanadaOdette Cancer Centre.Sunnybrook Health Sciences Centre.University of Toronta.Toronta.ON.temic therapy,and be offered referral to discuss risksCanadaDivision of MedicalOncoogy.University of Ottawa.Ottawa ON.CanadaDepartmentof Surgery.University of Ottawa.Ottawa ON.CanadaCentre de recherche du Centre Hospitalierand benefits with a medical oncologist.The panel feltthat one year of pembrolizumab is currently the onlyColumbia.Vancouver.BC.Canada IDepartment of Oncology.William Osler Health System.regimen that should be considered if adjuvant therapyBrampton.ON Canada:University of Manitoba Winnipeg.MB Canada:Department of Mecer Center,Calgary.AB Canadais selected.Panelists emphasized current opinions areVancouver.BC Canada:Department of Surgery,University of Montrea Montrea OC Canada:based on disease-free survival given the available results.Department of Radiation Oncology.Ottawa Hospital Research Institute.University of Ottawa.Ottawa.ON.Canada DepartmeSignificant uncertainty regarding the benefit and hammsof adjuvant therapy remains,primarily due to a lack ofOncology.Juravinski Cancer Centre,McMaster University.Hamiton.ON Canada IDivision ofUrology.Department of Surgery.McGill University.Montreal QC.Canada Division of Medicalconsistent benefit observed across similar trials of adju-Haifax,NS.of Urology and Ottawa Hospitalvant ICl-based therapies and immature overall survival(OS)data.Cite as:Lalani A-KL Kapoor A.Basappa NS et al Adjuvant therapy for renal cel carcinoma:2023Canadian Kidney Cancer Forum consensus statement Gan Ural Assoc/2023:17(5):E154-63.httpo//C